Sanofi has settled a long-running dispute with shareholders in the biotech Genzyme, who claimed the big pharma deliberately held back development of a multiple sclerosis drug to avoid payments ...

Genzyme, a subsidiary of Sanofi, has announced key data from its phase 3 clinical trials of its multiple sclerosis drug, Aubagio. The trials, called TOWER (Teriflunomide Oral in people With ...

Yuichi Iwaki, M.D., Ph.D., MediciNova CEO commented, “The successful resolution of the Sanofi-Novartis litigation and the resulting monetary damages due to MediciNova both validates the value of our ...

The therapy has clinically shown to be superior to Aubagio, another approved drug for multiple sclerosis by Sanofi Genzyme (SNY). "The acquisition of Ponvory is a significant milestone for Vanda ...